Publication | Closed Access

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

Breast OncologyOpen LabelMedicinePathologyPhase Ib TrialImmune Checkpoint InhibitorBreast CancerCancer TreatmentOncologyRadiation OncologyMolecular Oncology